NeuroPace, Inc. (NASDAQ:NPCE) Receives $16.60 Consensus Target Price from Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $16.60.

A number of analysts recently weighed in on NPCE shares. Zacks Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. JPMorgan Chase & Co. upped their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 14th. Wells Fargo & Company cut their target price on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Cantor Fitzgerald restated an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a research note on Wednesday, May 14th. Finally, HC Wainwright started coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They set a "buy" rating and a $18.00 target price on the stock.

NeuroPace Trading Up 4.3%

NASDAQ:NPCE traded up $0.37 on Tuesday, reaching $8.99. 156,232 shares of the company's stock were exchanged, compared to its average volume of 216,525. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. The firm has a market capitalization of $297.39 million, a price-to-earnings ratio of -10.70 and a beta of 1.89. The business has a fifty day moving average of $9.57 and a 200-day moving average of $11.53. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $23.52 million for the quarter, compared to analysts' expectations of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS. As a group, analysts expect that NeuroPace will post -1 earnings per share for the current year.

Hedge Funds Weigh In On NeuroPace

Hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its position in shares of NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock worth $27,000 after acquiring an additional 1,118 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of NeuroPace during the fourth quarter worth approximately $29,000. Legal & General Group Plc grew its position in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after acquiring an additional 1,239 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of NeuroPace during the second quarter worth approximately $35,000. Finally, GAMMA Investing LLC purchased a new position in shares of NeuroPace during the first quarter worth approximately $53,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.